Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5-EBOV Booster in Healthy Adults
NCT02533791Phase 1Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Jul 2015
- Primary completion
- Sep 2015
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Ad5-EBOV in Ebola virus disease (EVD) (3 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Occurrence of adverse reactions after vaccination at 7 days, Specific anti-EBOV antibody responses to the Ebola Zaire vaccine at 28 days and 1 more. Started Jul 2015; status: completed.
02
Drugs
Ad5-EBOV
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02533791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02533791.